AKBA Stock Risk & Deep Value Analysis
Akebia Therapeutics Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About AKBA Stock
We analyzed Akebia Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AKBA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is AKBA Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for AKBA?
- âš
Continued cash burn exceeding expectations
- âš
Further dilution through equity offerings
- âš
Failure to achieve sales targets for existing products
- âš
Increased competition in existing markets
- âš
Debt covenant breaches or refinancing challenges
Unlock AKBA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Akebia Therapeutics Inc (AKBA) Do?
Market Cap
$737.10M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit Akebia Therapeutics Inc WebsiteIs AKBA Stock Undervalued?
Unlock the full AI analysis for AKBA
Get the complete DVR score, risk analysis, and more
Does AKBA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
2 Identified
Akebia's existing products face significant competition and generic threats in the long term. The regulatory setback for vadadustat in the US severely impaired any potential wider moat from that asset. Without a new, differentiated asset or market capture, the company's competitive advantages are not durable.
Moat Erosion Risks
- •Further erosion of patent protection for Auryxia
- •Increased competition from new therapies for CKD-related conditions
- •Inability to differentiate Vafseo in ex-US markets against other HIF-PH inhibitors or erythropoiesis-stimulating agents (ESAs).
AKBA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive AKBA Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected mid-March 2026)
- •Updates on Auryxia commercial performance
- •Updates on Vafseo ex-US market penetration
Medium-Term (6-18 months)
- •Potential new business development or partnership announcements (highly speculative for growth)
- •Cost reduction initiatives yielding significant results
Long-Term (18+ months)
- •Acquisition of a transformative new pipeline asset (highly speculative and not currently indicated as a 10x driver)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for AKBA?
- ✓
Announcement of a new, game-changing pipeline asset acquisition or in-licensing agreement.
- ✓
Sustained quarter-over-quarter profitability and significant positive free cash flow.
- ✓
Major debt restructuring that significantly reduces financial leverage and dilution risk.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AKBA (Akebia Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
